# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jackie Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML037-SYN-TD
- Date: 1971-07-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marcus Delacroix-Hale, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- He is afraid of losing his sight and his independence **S**
- He wants to keep working and to stay strong for his family after his son's death **S**

## Your goals

- Vision kept or improved: proliferative disease regressed and macular edema reduced on anti-VEGF injections and laser. Target: 1971-10-26. Recorded outcome: Hemorrhage clearing, new vessels regressing after three injections and laser to the right eye; macular thickness down in both eyes; acuity improved. **S**
- A1c falling by about one point every three months without low blood sugar, to below 8% within six months and then below 7%. Target: 1971-10-26. Recorded outcome: 10.4% to 9.2% at three months; no low blood sugar. **S**
- Blood pressure below 130/80 mmHg. Target: 1971-10-26. Recorded outcome: 126/76 in the clinic. **S**
- LDL cholesterol below 55 mg/dL. Target: 1971-10-26. Recorded outcome: 142 to 74 mg/dL on atorvastatin 80 mg; ezetimibe added. **S**
- Walk at least three blocks without stopping, through supervised exercise. Target: 1971-10-26. Recorded outcome: From one block to two and a half blocks. **S**
- Feet kept intact: daily foot checks he can do with low vision, protective footwear, and prompt care for any skin break. Target: 1971-10-26. Recorded outcome: A heel blister found early, healed in five weeks; footwear provided. **S**
- Grief acknowledged and supported, with depression screening repeated. Target: 1971-10-26. Recorded outcome: Meeting the health center's grief counselor; PHQ-9 9 to 6. **S**

## What we agreed to do

- Urgent retina consultation within 48 hours for blurred vision with new floaters in a man with long-standing diabetes: dilated examination, OCT, and treatment of any proliferative retinopathy or macular edema; same-day attendance for a curtain over the vision or flashes. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); Diabetic Retinopathy Preferred Practice Pattern (2025) **S**
- Glucose: continue metformin and basal insulin, titrated slowly by a written plan so that the A1c falls gradually; rescue glucagon; diabetes self-management education adapted for low vision (a talking glucose meter, an insulin pen with audible dose clicks, large-print plans). Guideline: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026) **S**
- Cardiovascular risk: atorvastatin increased to 80 mg, aspirin continued, baseline ECG; cardiology evaluation of exertional chest tightness with a pharmacologic stress test, since calf pain limits walking. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026) **S**
- Legs and feet: comprehensive foot examination today; ankle-brachial index; daily foot checks with a magnifying mirror and a bright lamp, protective shoes; podiatry. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
- Kidneys: repeat urine albumin and kidney function after any change in kidney medicines; no NSAIDs. Guideline: 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Grief and mood: acknowledge the loss, PHQ-9 now and at three months, and an offer of the health center's grief counselor, which he accepted; call or text 988 if thoughts of self-harm ever arise. Guideline: 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Coronary disease, with cardiology: metoprolol succinate 25 mg daily and nitroglycerin as needed; continue high-intensity statin and aspirin; no revascularization now for a small area of ischemia with stable symptoms; review with cardiology in three months or sooner for worse or more frequent chest pain. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026) **S**
- Heel blister: daily dressing by the visiting nurse three times a week and by him on other days with a large-print guide; heel offloading shoe; podiatry within two days; review weekly; a vascular surgery opinion if it is not healing within four weeks or the ankle-brachial index is very low. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023) **S**
- On the retina specialist's advice: aflibercept injections in both eyes monthly for three doses, then treat-and-extend; panretinal photocoagulation to the right eye once the hemorrhage clears, and to the left if new vessels persist; vitrectomy if the hemorrhage does not clear within one to three months; low-vision evaluation; aspirin continued; glucose lowered gradually, and a GLP-1 receptor agonist only after the retina is stable, with retina review monthly. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); Diabetic Retinopathy Preferred Practice Pattern (2025); Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016) **S**
- Lisinopril increased to 40 mg and empagliflozin 10 mg started, with written sick-day rules; potassium and creatinine in four weeks; urine albumin at three months. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026) **S**
- Peripheral artery disease: supervised exercise therapy three times a week for twelve weeks once the heel has healed; podiatry every two to three months; vascular review if walking does not improve or any wound fails to heal. Guideline: 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023) **S**
- Dulaglutide 0.75 mg weekly started with the retina specialist's agreement, rising only if the retina stays stable at monthly review; ezetimibe 10 mg added; lipids four to eight weeks after the change, booked before he leaves the clinic. Guideline: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); Diabetic Retinopathy Preferred Practice Pattern (2025); Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026) **S**

## Follow-up

- 1971-07-27: Visit for blurred vision and new floaters, chest tightness on stairs, calf pain on walking and numb feet, in a man with long-standing diabetes six weeks after the death of his son **S**
- 1971-07-29: Review after the retina consultation and first eye injections: retinal diagnosis, glucose, blood pressure and kidney medicines **S**
- 1971-08-26: Four weeks after the new medicines: potassium and creatinine, blood pressure, ankle-brachial index, feet, mood, and the second eye injections **S**
- 1971-09-21: Periodic adult preventive visit **S**
- 1971-10-26: Three-month review: A1c, urine albumin, lipids, eyes after laser treatment, heart, legs, grief, and a GLP-1 receptor agonist **S**

This teaching document does not replace care from a qualified clinician.
